全文获取类型
收费全文 | 2709篇 |
免费 | 111篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 119篇 |
妇产科学 | 27篇 |
基础医学 | 335篇 |
口腔科学 | 31篇 |
临床医学 | 181篇 |
内科学 | 562篇 |
皮肤病学 | 58篇 |
神经病学 | 298篇 |
特种医学 | 101篇 |
外科学 | 329篇 |
综合类 | 42篇 |
预防医学 | 114篇 |
眼科学 | 171篇 |
药学 | 137篇 |
中国医学 | 3篇 |
肿瘤学 | 293篇 |
出版年
2023年 | 21篇 |
2022年 | 54篇 |
2021年 | 104篇 |
2020年 | 62篇 |
2019年 | 64篇 |
2018年 | 96篇 |
2017年 | 54篇 |
2016年 | 51篇 |
2015年 | 62篇 |
2014年 | 89篇 |
2013年 | 124篇 |
2012年 | 185篇 |
2011年 | 184篇 |
2010年 | 97篇 |
2009年 | 91篇 |
2008年 | 146篇 |
2007年 | 158篇 |
2006年 | 138篇 |
2005年 | 112篇 |
2004年 | 139篇 |
2003年 | 128篇 |
2002年 | 84篇 |
2001年 | 43篇 |
2000年 | 62篇 |
1999年 | 58篇 |
1998年 | 15篇 |
1997年 | 14篇 |
1996年 | 16篇 |
1995年 | 11篇 |
1994年 | 17篇 |
1993年 | 12篇 |
1992年 | 26篇 |
1991年 | 29篇 |
1990年 | 20篇 |
1989年 | 21篇 |
1988年 | 27篇 |
1987年 | 36篇 |
1986年 | 26篇 |
1985年 | 22篇 |
1984年 | 13篇 |
1983年 | 9篇 |
1982年 | 8篇 |
1980年 | 5篇 |
1979年 | 10篇 |
1977年 | 5篇 |
1975年 | 8篇 |
1973年 | 10篇 |
1972年 | 13篇 |
1971年 | 13篇 |
1970年 | 5篇 |
排序方式: 共有2820条查询结果,搜索用时 312 毫秒
41.
42.
Aman U Buzdar Nuhad K Ibrahim Deborah Francis Daniel J Booser Eva S Thomas Richard L Theriault Lajos Pusztai Marjorie C Green Banu K Arun Sharon H Giordano Massimo Cristofanilli Debra K Frye Terry L Smith Kelly K Hunt Sonja E Singletary Aysegul A Sahin Michael S Ewer Thomas A Buchholz Donald Berry Gabriel N Hortobagyi 《Journal of clinical oncology》2005,23(16):3676-3685
PURPOSE: The objective of this study was to determine whether the addition of trastuzumab to chemotherapy in the neoadjuvant setting could increase pathologic complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2) -positive disease. PATIENTS AND METHODS: Forty-two patients with HER2-positive disease with operable breast cancer were randomly assigned to either four cycles of paclitaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide or to the same chemotherapy with simultaneous weekly trastuzumab for 24 weeks. The primary objective was to demonstrate a 20% improvement in pCR (assumed 21% to 41%) with the addition of trastuzumab to chemotherapy. The planned sample size was 164 patients. RESULTS: Prognostic factors were similar in the two groups. After 34 patients had completed therapy, the trial's Data Monitoring Committee stopped the trial because of superiority of trastuzumab plus chemotherapy. pCR rates were 25% and 66.7% for chemotherapy (n = 16) and trastuzumab plus chemotherapy (n = 18), respectively (P = .02). The decision was based on the calculation that, if study continued to 164 patients, there was a 95% probability that trastuzumab plus chemotherapy would be superior. Of the 42 randomized patients, 26% in the chemotherapy arm achieved pCR compared with 65.2% in the trastuzumab plus chemotherapy arm (P = .016). The safety of this approach is not established, although no clinical congestive heart failure was observed. A more than 10% decrease in the cardiac ejection fraction was observed in five and seven patients in the chemotherapy and trastuzumab plus chemotherapy arms, respectively. CONCLUSION: Despite the small sample size, these data indicate that adding trastuzumab to chemotherapy, as used in this trial, significantly increased pCR without clinical congestive heart failure. 相似文献
43.
44.
Stan Kutcher Michael Aman Sarah J Brooks Jan Buitelaar Emma van Daalen J?rg Fegert Robert L Findling Sandra Fisman Laurence L Greenhill Michael Huss Vivek Kusumakar Daniel Pine Eric Taylor Sam Tyano 《European neuropsychopharmacology》2004,14(1):11-28
Researchers and clinicians worldwide share concerns that many youngsters with attention-deficit/hyperactivity disorder (ADHD) and/or disruptive behaviour disorders (DBDs) do not receive appropriate treatment despite availability of effective therapies. At the request of Johnson and Johnson (sponsor), 11 international experts in child and adolescent psychiatry were selected by Professor Stan Kutcher (chair) to address these concerns. This paper describes the experts' consensus conclusions, including treatment practice suggestions for physicians involved in the early treatment of youngsters with ADHD (or hyperkinetic disorder, in countries preferring this classification) and/or DBDs internationally: suggested first-line treatment for ADHD without comorbidity is psychostimulant medication aided by psychosocial intervention. For ADHD with comorbid conduct disorder (CD), psychosocial intervention combined with pharmacotherapy is suggested. For primary CD, suggested first-line treatment is psychosocial intervention, with pharmacotherapy considered as an 'add-on' when aggression/impulsivity is marked and persistent. Pharmacotherapy requires careful titration; full-day coverage is the suggested goal. Regular long-term follow-up is recommended. 相似文献
45.
46.
47.
This case report describes rare intraoperative complications during renal allotransplantation. A 59-year-old man underwent an expanded criteria deceased donor renal transplantation. A wedge biopsy, as per institution protocol, was performed prior to surgery. After vascular anastomoses, the kidney was reperfused; immediate significant hematuria was noted from the ureter. After exploration, compression of the wedge biopsy site stopped the bleeding, suggesting a venous-calyceal fistula. An incision at the wedge biopsy site was made to do an open repair, yielding a small suspicious lesion. Frozen section confirmed clear cell renal carcinoma, which was completely resected. The hematuria resolved after renorrhaphy, and we proceeded with ureteral reimplantation. Postoperatively, the patient was maintained on immunosuppression, free of recurrence at eight months. The surgeon must be aware of the possibilities of unusual complications as well as treatment options. This study provides a treatment strategy to address these challenging intraoperative complications. 相似文献
48.
49.
50.
The advent of biologics in dermatologic treatment armentarium has added refreshing dimensions, for it is a major breakthrough. Several agents are now available for use. It is therefore imperative to succinctly comprehend their pharmacokinetics for their apt use. A concerted endeavor has been made to delve on this subject. The major groups of biologics have been covered and include: Drugs acting against TNF-α, Alefacept, Ustekinumab, Rituximab, IVIG and Omalizumab. The relevant pharmacokinetic characteristics have been detailed. Their respective label (approved) and off-label (unapproved) indications have been defined, highlighting their dosage protocol, availability and mode of administration. The evidence level of each indication has also been discussed to apprise the clinician of their current and prospective uses. Individual anti-TNF drugs are not identical in their actions and often one is superior to the other in a particular disease. Hence, the section on anti-TNF agents mentions the literature on each drug separately, and not as a group. The limitations for their use have also been clearly brought out. 相似文献